Even in the absence of PD-L1 expression, the combination of Pembrolizumab with selected combined chemotherapy (CT) showed OS advantage over that of CT alone in metastatic NSCLC [11]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.